Lisata Therapeutics Inc. (LSTA)
NASDAQ: LSTA
· Real-Time Price · USD
2.44
-0.06 (-2.20%)
At close: Jun 13, 2025, 3:58 PM
-2.20% (1D)
| Bid | 2.28 |
| Market Cap | 20.98M |
| Revenue (ttm) | 1M |
| Net Income (ttm) | -19.31M |
| EPS (ttm) | -2.3 |
| PE Ratio (ttm) | -1.06 |
| Forward PE | -2.64 |
| Analyst | Buy |
| Ask | 2.69 |
| Volume | 3,211 |
| Avg. Volume (20D) | 12,628 |
| Open | 2.50 |
| Previous Close | 2.50 |
| Day's Range | 2.44 - 2.50 |
| 52-Week Range | 1.87 - 4.20 |
| Beta | 1.00 |
About LSTA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LSTA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LSTA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
-29.49%
Lisata Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
9 months ago
+6.53%
Lisata Therapeutics shares are trading higher after the company announced its first patient was treated in the second-line cholangiocarcinoma cohort of the BOLSTER trial.
1 month ago · proactiveinvestors.com
Lisata eyes key trial milestones in 2025 as certepetide development gains momentumLisata Therapeutics Inc (NASDAQ:LSTA) said on Thursday it expects a data-rich year ahead as it advances multiple trials of its lead asset, certepetide, a novel peptide-based therapy being tested in a ...
1 month ago · proactiveinvestors.com
Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMILisata Therapeutics Inc earlier this week discussed the potential of certepetide in antibody-drug conjugate (ADC) applications through a new collaboration with Catalent. The company told investors tha...
